Nitrol and Ferrlecit drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Nitrol (nitroglycerin) and Ferrlecit (sodium ferric gluconate complex). Common drug interactions include arteriovenous fistula site complication among females and device related infection among males.

The phase IV clinical study analyzes what interactions people have when they take Nitrol and Ferrlecit. It is created by eHealthMe based on reports of 17 people who take the same drugs from the FDA, and is updated regularly.

What is Nitrol?

Nitrol has active ingredients of nitroglycerin. eHealthMe is studying from 3,069 Nitrol users. Check the latest studies of Nitrol.

What is Ferrlecit?

Ferrlecit has active ingredients of sodium ferric gluconate complex. eHealthMe is studying from 2,376 Ferrlecit users. Check the latest studies of Ferrlecit.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

17 people who take Nitrol and Ferrlecit together, and have interactions are studied.

What are the common drug interactions of Nitrol and Ferrlecit, by gender? *:

female:

Arteriovenous fistula site complication
Hypervolaemia (abnormally increased volume of blood)
Sudden death
Anaemia (lack of blood)
Aplasia pure red cell (type of anaemia affecting the precursors to red blood cells but not to white blood cells)
Cardiac failure acute
Inflammatory marker increased
Plasma cell myeloma (cancer that begins in plasma cells)
Shunt occlusion (blockage of shunt)
Therapeutic response decreased (less preventive response)

male:

Device related infection
Epistaxis (bleed from the nose)
Lymphangitis (inflammation of the lymph channel)
Post procedural complication
Blood parathyroid hormone increased
Hypocalcaemia (levels of calcium in blood serum are abnormally low)

What are the common drug interactions of Nitrol and Ferrlecit, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Device related infection
Epistaxis (bleed from the nose)
Lymphangitis (inflammation of the lymph channel)
Post procedural complication
Blood parathyroid hormone increased
Hypocalcaemia (levels of calcium in blood serum are abnormally low)
Anaemia (lack of blood)
Aplasia pure red cell (type of anaemia affecting the precursors to red blood cells but not to white blood cells)
Plasma cell myeloma (cancer that begins in plasma cells)
Therapeutic response decreased (less preventive response)

60+:

Mobility decreased (ability to move is reduced)
Pain in extremity
Shunt occlusion (blockage of shunt)
Hypervolaemia (abnormally increased volume of blood)
Sudden death
Ascites (accumulation of fluid in the abdominal cavity)
Brain stem ischaemia (a condition in which there is insufficient blood flow to the brain to meet metabolic demand)
Cardiac failure acute
Inflammatory marker increased
Pleural effusion (water on the lungs)

What are the existing conditions these people have? *

Polyneuropathy (neurological disorder that occurs when many peripheral nerves throughout the body malfunction simultaneously): 3 people, 17.65%
Osteoporosis (bones weak and more likely to break): 3 people, 17.65%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 17.65%
Haemodilution (increase in the volume of plasma in relation to red blood cells): 3 people, 17.65%
Transitional Cell Carcinoma (cancer tumour inner most layer of urinary system): 1 person, 5.88%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 1 person, 5.88%
Infection: 1 person, 5.88%
Indigestion: 1 person, 5.88%
Hyperparathyroidism Secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary): 1 person, 5.88%
Hyperlipidaemia (presence of excess lipids in the blood): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Nitrol and Ferrlecit?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously